coronavirus vaccine.The Saskatoon-based lab at the University of Saskatchewan received the green light from Health Canada to start Phase 1 of its clinical vaccine trials.“The approval to initiate a human clinical trial is a milestone for VIDO,” Dr.
Volker Gerdts, director and CEO of the Vaccine and Infectious Disease Organization (VIDO), said in a statement Tuesday.“This is the first of our two COVID-19 subunit vaccines in development and demonstrates the quality of our research, development and partnerships.” USask’s Vido-InterVac nearing human clinical trials for COVID-19 vaccine Gerdts said it is possible VIDO could have one of its vaccines ready to use by late 2021.“To have sustainable long-term vaccine access, I think it’s important.